Loading...
Dr. Reddy's delivered a strong quarter with $992M in revenue and a 14% YoY increase in net income, despite declines in North America due to price erosion in Lenalidomide.
Dr. Reddy’s delivered strong Q4 FY25 performance with 20% revenue growth and 22% increase in net income, fueled by strategic acquisitions and robust sales in key markets.